Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Edwards

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Plant Molecular Biology|May 10, 2002
Toward positional cloning of Vgt1, a QTL controlling the transition from the vegetative to the reproductive phase in maizeSilvio Salvi, Roberto Tuberosa, Elena Chiapparino, et al.
BMC Neurology|November 27, 2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialJonathan Calkwood, Bruce Cree, Heidi Crayton, et al.
Plos One|February 24, 2021
Detecting SARS-CoV-2 variants with SNP genotypingHelen Harper, Amanda Burridge, Mark Winfield, et al.
Scientific Reports|September 25, 2020
Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deteriorationMario Amatruda, Maria Petracca, Maureen Wentling, et al.
Multiple Sclerosis and Related Disorders|August 13, 2015
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisEdward Fox, Keith Edwards, Gordon Burch, et al.
Journal of Comparative Effectiveness Research|February 14, 2019
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR studyRobert Zivadinov, Kiren Kresa-Reahl, Bianca Weinstock-Guttman, et al.
Brain : a Journal of Neurology|December 11, 2021
Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasmaAchilles Ntranos, Hye-Jin Park, Maureen Wentling, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 8, 2019
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapyStanley L Cohan, Keith Edwards, Lindsay Lucas, et al.
Vaccines|May 28, 2022
COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough InfectionsDejan Jakimovski, Karen Zakalik, Samreen Awan, et al.
Trials|January 29, 2016
Improving delivery of secondary prophylaxis for rheumatic heart disease in remote Indigenous communities: study protocol for a stepped-wedge randomised trialAnna P Ralph, Clancy Read, Vanessa Johnston, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Plant Molecular Biology|May 10, 2002
Toward positional cloning of Vgt1, a QTL controlling the transition from the vegetative to the reproductive phase in maizeSilvio Salvi, Roberto Tuberosa, Elena Chiapparino, et al.
BMC Neurology|November 27, 2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialJonathan Calkwood, Bruce Cree, Heidi Crayton, et al.
Plos One|February 24, 2021
Detecting SARS-CoV-2 variants with SNP genotypingHelen Harper, Amanda Burridge, Mark Winfield, et al.
Scientific Reports|September 25, 2020
Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deteriorationMario Amatruda, Maria Petracca, Maureen Wentling, et al.
Multiple Sclerosis and Related Disorders|August 13, 2015
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisEdward Fox, Keith Edwards, Gordon Burch, et al.
Journal of Comparative Effectiveness Research|February 14, 2019
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR studyRobert Zivadinov, Kiren Kresa-Reahl, Bianca Weinstock-Guttman, et al.
Brain : a Journal of Neurology|December 11, 2021
Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasmaAchilles Ntranos, Hye-Jin Park, Maureen Wentling, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 8, 2019
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapyStanley L Cohan, Keith Edwards, Lindsay Lucas, et al.
Vaccines|May 28, 2022
COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough InfectionsDejan Jakimovski, Karen Zakalik, Samreen Awan, et al.
Trials|January 29, 2016
Improving delivery of secondary prophylaxis for rheumatic heart disease in remote Indigenous communities: study protocol for a stepped-wedge randomised trialAnna P Ralph, Clancy Read, Vanessa Johnston, et al.
Pageof 4